Which companies are Heartseed's closest peers?

The cockpit's peer set: SanBio (4592.T), Tiansheng Pharmaceutical (002872.SZ), Zota Health Care (ZOTA.NS), iX Biopharma (42C.SI), Tuoxin Pharmaceutical (301089.SZ), MapLight Therapeutics (MPLT), Kwality Pharmaceuticals (KPL.NS), Hyundai Bioscience (048410.KS).

How has Heartseed stock performed?

Over six months to 6 Nov 2026 the shares returned +51.9% against -16.1% for the median peer; over one year +45.9%.

← CockpitCompetitor Analysis › 219A.T Heartseed, Inc.Open in the cockpit ↗

Heartseed, Inc.219A.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Momentum leader 98

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$393M

US dollars, full cap

Free float

57%

of shares outstanding

$/day

$9.35M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

n/a

WACC 6.0%

Hurdle

-23 pp

Req g minus delivered

Next earnings

7 days

13 Nov 2026

Close · JPY¥2,700

1D-7.4%

1W-12.6%

1M-3.6%

3M+61.7%

6M+51.9%

YTD+49.7%

1Y+45.9%

ATR %6.9%

52w lowhigh15.9% off high

What Heartseed does

Employees: 43

Heartseed at a glance

Size Heartseed (219A.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $393M, the 1195th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥2,700 on 6 Nov 2026.

Performance Over six months the shares gained 51.9%, against -16.1% for the median peer and +1.8% for the Japan market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 196.9% over the last twelve months (peer median +7.3%); the operating margin is 9.0% (peer median -13.0%).

Valuation It trades at 21.4× enterprise value to sales against a peer median of 5.8× (4th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 50% a year for seven years (Req g). Recent delivered growth is +73%, so the hurdle is -23 pp: the price already allows for a slowdown.

Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Heartseed against the median of its 20 peers (local-currency closes).

Heartseed financials

Reported figures in JPY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	n/a	¥2.59B	¥874M	¥345M	¥499M
Revenue growth	—	+197%	+153%	-31%	—
EBITDA	n/a	¥279M	-¥997M	-¥1.45B	-¥1.46B
Net income	n/a	¥163M	-¥813M	-¥1.47B	-¥1.41B
Free cash flow	n/a	¥1.05B	-¥1.36B	-¥1.13B	-¥1.92B
Capital expenditure	n/a	¥28.7M	¥14.0M	¥328M	¥0
Total debt	¥0	¥252,000	¥5.39M	¥11.6M	¥31.0M

Quarterly statements and history in the cockpit →

Heartseed competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Heartseed is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Heartseed is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Heartseed is the large dot.

Heartseed competitors and peer comparison

How Heartseed compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Heartseed against its 20 peers (data as of 6 Nov 2026)
Measure	219A.T	Peer median	Rank in peer set
1-month return	-3.6%	-11.9%	6th highest of 21
6-month return	+51.9%	-16.1%	2nd highest of 21
Distance from 52-week high	-15.9%	-39.0%	3rd highest of 21
Revenue growth (TTM)	+196.9%	+7.3%	highest of 18
Operating margin	9.0%	-13.0%	4th highest of 18
EV / Sales	21.4×	5.8×	4th most expensive of 18
Growth the price implies (Req g, 7 yrs)	50.0%	4.2%	most demanding of 8
Growth delivered (Del g)	+73.2%	+3.1%	highest of 8
Hurdle (Req g minus delivered)	-23.2 pp	+1.1 pp	2nd least demanding of 8
Net debt / EBITDA	-22.7×	0.9×	least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Heartseed 219A.T	Japan	$393M	+52%	+197%	9%	21.4×	50.0%	+73.2%
SanBio 4592.T	Japan	$393M	-58%	n/a	n/a	n/a	n/a	n/a
Tiansheng Pharmaceutical 002872.SZ	China	$392M	+15%	-1%	-13%	5.2×	23.2%	-15.7%
Zota Health Care ZOTA.NS	India	$395M	-6%	+69%	-16%	5.8×	n/a	n/a
iX Biopharma 42C.SI	Singapore	$386M	+10%	-12%	-140%	70.7×	n/a	n/a
Tuoxin Pharmaceutical 301089.SZ	China	$400M	-22%	+17%	-20%	5.8×	n/a	n/a
MapLight Therapeutics MPLT	United States	$385M	-75%	n/a	n/a	n/a	n/a	n/a
Kwality Pharmaceuticals KPL.NS	India	$401M	+111%	+38%	21%	6.8×	n/a	n/a
Hyundai Bioscience 048410.KS	South Korea	$401M	-58%	+78%	-580%	158.2×	n/a	n/a
Guangdong Lifestrong Pharmacy 301111.SZ	China	$401M	-16%	+7%	-2%	7.9×	n/a	n/a
JW Pharmaceutical 001060.KS	South Korea	$402M	-28%	+10%	14%	0.7×	-16.9%	+7.2%
JCR Pharmaceuticals 4552.T	Japan	$383M	-11%	+3%	-14%	2.9×	n/a	n/a
Shandong Sinobioway Biomedicine 002581.SZ	China	$404M	-40%	+91%	-65%	7.8×	n/a	n/a
Guizhou Yibai Pharmaceutical 600594.SS	China	$376M	-21%	-26%	-15%	2.0×	9.0%	-11.3%
Hansa Biopharma HNSA.ST	Sweden	$410M	+39%	-4%	-304%	23.7×	n/a	n/a
Shaanxi Panlong Pharmaceutical 002864.SZ	China	$411M	-13%	-9%	9%	1.6×	-0.4%	+11.2%
Rezolute RZLT	United States	$375M	+21%	n/a	n/a	n/a	n/a	n/a
Anhui Sunhere Pharmaceutical Excipients 300452.SZ	China	$412M	-16%	+9%	19%	2.4×	-4.5%	+12.1%
Unichem Laboratories UNICHEMLAB.NS	India	$373M	+28%	+9%	5%	1.5×	n/a	n/a
Chongqing Hifuture Information Technology 002168.SZ	China	$372M	-23%	+2%	-6%	8.3×	16.3%	-14.0%
Anhui Fengyuan Pharmaceutical 000153.SZ	China	$372M	-17%	-24%	3%	1.1×	4.2%	+3.1%

Questions

Which companies are Heartseed's closest peers?: The cockpit's peer set: SanBio (4592.T), Tiansheng Pharmaceutical (002872.SZ), Zota Health Care (ZOTA.NS), iX Biopharma (42C.SI), Tuoxin Pharmaceutical (301089.SZ), MapLight Therapeutics (MPLT), Kwality Pharmaceuticals (KPL.NS), Hyundai Bioscience (048410.KS).
Is Heartseed expensive compared with its peers?: On ev / sales it trades at 21.4× against a peer median of 5.8×, 4th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 50% a year for seven years (Req g). Recent delivered growth is +73%, so the hurdle is -23 pp: the price already allows for a slowdown.
How has Heartseed stock performed?: Over six months to 6 Nov 2026 the shares returned +51.9% against -16.1% for the median peer; over one year +45.9%.